Baillie Gifford & Co. Buys 34,947 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Baillie Gifford & Co. lifted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 14.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 269,836 shares of the company's stock after purchasing an additional 34,947 shares during the period. Baillie Gifford & Co. owned about 0.80% of TransMedics Group worth $16,824,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Clear Creek Financial Management LLC bought a new stake in shares of TransMedics Group during the 4th quarter worth $352,000. Vaughan Nelson Investment Management L.P. raised its stake in shares of TransMedics Group by 9.9% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock worth $22,547,000 after purchasing an additional 32,605 shares during the period. State of Alaska Department of Revenue bought a new stake in shares of TransMedics Group during the 3rd quarter worth $2,560,000. Charles Schwab Investment Management Inc. raised its stake in TransMedics Group by 2.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company's stock valued at $42,656,000 after acquiring an additional 6,634 shares during the period. Finally, Zacks Investment Management bought a new stake in TransMedics Group in the 3rd quarter valued at about $1,607,000. 99.67% of the stock is currently owned by institutional investors.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the business's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares of the company's stock, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.00% of the stock is owned by insiders.

TransMedics Group Price Performance

Shares of TMDX traded down $3.50 during midday trading on Friday, hitting $71.95. 1,192,967 shares of the company traded hands, compared to its average volume of 2,186,507. The stock has a 50-day moving average of $66.47 and a 200-day moving average of $105.05. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The firm has a market cap of $2.41 billion, a P/E ratio of 76.54 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Robert W. Baird lowered their price objective on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a research note on Wednesday, December 11th. TD Cowen lowered their price objective on TransMedics Group from $175.00 to $120.00 and set a "buy" rating on the stock in a research note on Monday, November 18th. Oppenheimer restated an "outperform" rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. restated a "neutral" rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.